Compare FTK & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTK | DRUG |
|---|---|---|
| Founded | 1985 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 445.8M | 364.8M |
| IPO Year | N/A | N/A |
| Metric | FTK | DRUG |
|---|---|---|
| Price | $16.15 | $82.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $16.00 | ★ $83.00 |
| AVG Volume (30 Days) | ★ 318.3K | 156.1K |
| Earning Date | 11-04-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 242.12 | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $220,501,000.00 | N/A |
| Revenue This Year | $20.33 | N/A |
| Revenue Next Year | $12.59 | N/A |
| P/E Ratio | $17.09 | ★ N/A |
| Revenue Growth | ★ 23.56 | N/A |
| 52 Week Low | $6.05 | $23.18 |
| 52 Week High | $18.96 | $97.75 |
| Indicator | FTK | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 58.85 | 60.74 |
| Support Level | $15.01 | $77.80 |
| Resistance Level | $16.98 | $97.75 |
| Average True Range (ATR) | 0.83 | 8.69 |
| MACD | 0.05 | 0.27 |
| Stochastic Oscillator | 82.33 | 59.91 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.